Amylyx Pharmaceuticals Inc (AMLX) has provided an announcement.
Amylyx Pharmaceuticals, Inc. has strengthened its Board of Directors by bringing on Bernhardt Zeiher, MD, as a Class I director, with his term extending to the 2025 annual stockholders’ meeting. His extensive industry experience includes a prominent tenure as Chief Medical Officer at Astellas Pharma and participation in several influential boards. Zeiher steps into a role on the Nominating and Corporate Governance Committee, succeeding Paul Fonteyne, and is set to receive a comprehensive compensation package including annual retainers and stock options under the company’s Non-Employee Director Compensation Policy.
See more data about AMLX stock on TipRanks’ Stock Analysis page.
